Estrogen drives gut pain and explains higher rates of IBS in women

https://www.news-medical.net/news/20251218/Estrogen-drives-gut-pain-and-explains-higher-rates-of-IBS-in-women.aspx

HPV vaccination reduces risk of vulvar and vaginal lesions

https://www.news-medical.net/news/20251218/HPV-vaccination-reduces-risk-of-vulvar-and-vaginal-lesions.aspx

Whooping cough cases rise sharply across the United States

https://www.news-medical.net/news/20251218/Whooping-cough-cases-rise-sharply-across-the-United-States.aspx

Roadmap for Engaging the Public as Partners in Clinical Research

https://www.nih.gov/about-nih/nih-director/statements/roadmap-engaging-public-partners-clinical-research ROADMAP FOR ENGAGING THE PUBLIC AS PARTNERS IN CLINICAL RESEARCH https://osp.od.nih.gov/wp-content/uploads/2025/12/NExTRACs-ENGAGE-Report_FINAL.pdf At the National Institutes of Health (NIH), engendering trust and confidence in the research we support is one of our top priorities. Three things guide these efforts: engaging in open, honest dialogue, acting in transparency, and delivering on our commitment to advancing science and improving health. To help guide this work, the Novel and Exceptional Technology and Research Advisory Committee (NExTRAC) recently undertook a multi-year effort to provide the NIH with a roadmap for incorporating public voices in clinical research (see NExTRAC report) . Deliberations were informed by a team of multi-disciplinary experts and community conversations across the country , specifically asked to think about strategies for incorporating public voices at every stage of the clinical research process. https://partnersinresearch.nih.gov/members/ I am pleased to endorse these recommendations, which focus on: --providing a clear vision and framework for maximally involving patients and communities in clinical research; --ensuring that people and communities have meaningful input into the agenda and direction of research that is relevant and impactful for them; and --increasing transparency for how research participant data are utilized in moving the scientific enterprise forward. NIH is eager to begin implementing this roadmap, starting in 2026. First, NIH will work with the community to make the return of participant research results standard practice. Initial efforts will focus on returning summary-level research results, with the intent of augmenting practices that result in returning individual-level research results to research participants. Providing individuals with their research data so they can make their own healthcare decisions is one of my top priorities as NIH Director. NIH is also working towards harnessing the widespread adoption of electronic health records and other large scale electronic clinical information systems to accelerate biomedical research in ways not previously possible. In the spirit of transparency, NIH is establishing agency-wide principles to foster, promote, and guide the responsible conduct of research using clinical data. These principles serve as an initial transparent foundation for building trust with the public in how their data are respected and shared to drive improvements in health across the country. I want to thank the NExTRAC and the ENGAGE Working Group members for their keen insights and thoughtful deliberations. Their efforts will serve as a valuable tool toward improving the health of all Americans. Dr. Jay Bhattacharya NIH Director About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit . NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This Statement is available online at:

Studies on nano magnesium oxide modified acrylic resin in antibacterial coating application Tirthankar Jana* [1] , Tapan Kumar Dhar [1]

https://www.academia.edu/2997-2027/2/4/10.20935/AcadMatSci8044 The present study is related to the impact of nano magnesium oxide modified hybrid acrylic resin as a dual functional component in coating applications. Such nano magnesium oxide modified hybrid acrylic acts as a film former as well as antimicrobial agent. Nano magnesium oxide modification into acrylic resin was carried out through chemical modification with specially designed acrylic resin and confirmed by IR spectroscopic and SEM analysis. The effect of nano magnesium oxide modified hybrid acrylic resin was evaluated in water-based paint composition and compared against acrylic paint containing commercial biocides. The results revealed enhancement of coating properties like opacity (5%), whiteness (6%), gloss (7.5%) and antibacterial performance (more than 99% reduction of bacterial concentration) in magnesium oxide modified acrylic paint against unmodified ones and comparable with paint properties containing commercial biocides. The study shows that specially designed nano MgO modified acrylic resin can be used to make antibacterial coating without using commercial biocides.

Patients’ Insights Illuminated: A Rapid-Fire Dive Into CLL and MCL Authors: Lorna Warwick; Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD; Nicole Lamanna, MD; David Ball; Vivienne Ball

https://www.medscape.org/viewarticle/1002737?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251219-OUS-HONC-1002737-cta

Shaping the Future: Expert Insights on Perioperative Immunotherapy for Gastric/GEJ Cancers Authors: Elizabeth Smyth, MD; Samuel J. Klempner, MD, FASCO, Eric Van Cutsem, MD, PhD

https://www.medscape.org/viewarticle/1002919?sso=true&uac=148436CN&src=mkmcmr_driv_32025_mscpedu_416293.16_ace_launch

Editorial p1 Diabetes and cancer in the age of multimorbidity The Lancet Diabetes & Endocrinology +++ +...

Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, multicentre, multinational, randomised controlled trial https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00288-8/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-8oahYvG7-CTIpexG2ufMYg9LmcjPbh_mwLweZG_RpaEP-d27IncgR96wwCaRbbLpxJ_r_LeD14yaG0wRzYb6Oo7mzrlQ&_hsmi=395126969&utm_content=395109551&utm_source=hs_email Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00285-2/fulltext?dgcid=hubspot_update_feature_updatealerts_landia&utm_campaign=update-landia&utm_medium=email&_hsenc=p2ANqtz--AqoYIv0zQvdHrMjQMR6McVJQwTmZHyWrb2QZI0S02GJsgMLX0geOytTrSeHFEQlLbowHeMdNkBypPnJUpjVp4RHMbFw&_hsmi=395126969&utm_content=395109551&utm_source=hs_email Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based study https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00265-7/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-9KJPrux5d3_Kw96kWlaJ4pJyaqnpDQs9wPeXVKGsPZ16U2_jv6jBgw56s0N7_r28rH-_7nLNjewVV2RVo-0R_SIu2IoA&_hsmi=395126969&utm_content=395109551&utm_source=hs_email Editorial p1 Diabetes and cancer in the age of multimorbidity The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/issue/vol14no1/PIIS2213-8587(25)X0013-9

Editorial p1 Turning policy into action for brain health The Lancet Neurology +++ +...

Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00386-2/fulltext?dgcid=hubspot_update_feature_updatealerts_laneur&utm_campaign=update-laneur&utm_medium=email&_hsenc=p2ANqtz--C4hczGmVdXlcmcdW6Yg16xrTGqF5t1vXghIfIZjUmUv-kPI3oMMj3UpCyklcM8Ks4zaUXkb0_n7nBO3BbVwNONu1s3A&_hsmi=395117155&utm_content=395108665&utm_source=hs_email Seizure-related biomarkers of sudden unexpected death in epilepsy (SUDEP) in drug-resistant focal epilepsy (REPO2MSE): a prospective, multicentre case–control study https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00379-5/fulltext?dgcid=hubspot_update_feature_updatealerts_laneur&utm_campaign=update-laneur&utm_medium=email&_hsenc=p2ANqtz--2Qir_Kag4S30b-jCQR2M0StqZeVbpMlz-qvSkO7yaQ8UrGiY4LMXqOKihPXhT9SSFmX07WXmOa_dBOElo_qZi29teCQ&_hsmi=395117155&utm_content=395108665&utm_source=hs_email Endovascular thrombectomy for acute stroke: evolving eligibility criteria and adjunct therapies https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00356-4/abstract?utm_campaign=update-laneur&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_laneur&_hsenc=p2ANqtz-9Ww4b67TfrrvF8J_V-wrRbrONovM7RIrF4z9HLLSmiceMGFAt0RUsKGxw1RJZ80lwemCM30GLTWsB4wVvtddVKtB2-HQ&_hsmi=395117155&utm_content=395108665&utm_source=hs_email Editorial p1 Turning policy into action for brain health The Lancet Neurology https://www.thelancet.com/journals/laneur/issue/vol25no1/PIIS1474-4422(25)X0013-2

Read Cancer Science & Oncogenesis +...

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_251219

Cutting carbs, not fat, may better control appetite in women +++++

Cutting carbs, not fat, may better control appetite in women https://www.news-medical.net/news/20251219/Cutting-carbs-not-fat-may-better-control-appetite-in-women.aspx A short-term clinical trial suggests that cutting carbohydrates, not fat, may be better for curbing food cues and emotional eating in women living with lipedema. Purple Power: Evidence-Based Health Benefits of Anthocyanin-Rich Diets https://www.news-medical.net/health/Purple-Power-Evidence-Based-Health-Benefits-of-Anthocyanin-Rich-Diets.aspx Purple foods aren’t just pretty! Here’s what anthocyanins are actually doing inside your body, and why the best evidence points to specific heart and brain benefits (with skin protection emerging). Chrononutrition Explained: Why When You Eat Matters for Metabolic Health https://www.news-medical.net/health/Chrononutrition-Explained-Why-When-You-Eat-Matters-for-Metabolic-Health.aspx Late-night meals can quietly derail glucose control and cardiovascular health. Here’s what chrononutrition research and clinical evidence suggest you should eat, avoid, and shift earlier to protect metabolic function. How Artificial Food Coloring Affects Children's Behavior and Health https://www.news-medical.net/health/How-Artificial-Food-Coloring-Affects-Children-Behavior-and-Health.aspx Synthetic food dyes are widely used in packaged foods and can disproportionately affect children due to higher relative intake and developmental vulnerability. Evidence from clinical trials, animal studies, and regulatory reviews links certain dyes to behavioral changes, allergic reactions, and emerging concerns involving the gut–brain axis. Early peanut introduction can prevent allergy but parents need clearer guidance https://www.news-medical.net/news/20251218/Early-peanut-introduction-can-prevent-allergy-but-parents-need-clearer-guidance.aspx

Analytical Results of Testing Food for PFAS from Environmental Contamination

https://www.fda.gov/food/environmental-contaminants-food/analytical-results-testing-food-pfas-environmental-contamination?utm_medium=email&utm_source=govdelivery FDA Releases Additional 2024 PFAS Results Results for Six Additional TDS Regional Collections Added to Database View on the FDA Website December 19, 2025 Constituent Update Today, the FDA is sharing per- and polyfluoroalkyl substances (PFAS) results for six additional Total Diet Study (TDS) regional collections collected in 2024, adding to the eight TDS collections already posted on the Analytical Results of Testing Food for PFAS from Environmental Contamination webpage. The goal of this ongoing sampling is to better understand background contamination levels, U.S. consumers’ average exposure to PFAS from foods, prioritize foods for future monitoring, and guide further FDA activities. A summary of PFAS results for these six additional TDS collections are as follows: 503 of 542 (92.8%) samples had no detections 39 of 542 (7.2%) samples had trace detections of one or more PFAS analytes: cod, shrimp, clams, salmon, tilapia, catfish pepperoni, beef steak, ground beef, chicken breast half & half, whole milk, skim milk kale 4 of 39 samples had non-trace detections of one or more PFAS analytes: shrimp, clams catfish, tilapia To estimate dietary exposure to PFAS from the general food supply, the FDA has been testing fresh and processed foods for certain PFAS since 2019. Results for PFAS testing of TDS samples began for the first time in 2019. It is important to note that to date no PFAS have been detected in 95% (1,290 out of 1,352) of the fresh and processed foods tested from the TDS. TDS data can show how much contamination is present and help estimate possible exposure, but they should not be used on their own to decide whether something is safe or harmful to health. In the past six years, the FDA has made significant progress in understanding PFAS and is leading the science in developing validated methods for testing for PFAS in increasingly diverse types of foods. Based on our validated methods, FDA currently tests for up to 30 PFAS in various foods, including bread and grains; fruits and vegetables; meat, eggs, and dairy products, including milk; and seafood. To date, the FDA has tested over 1,900 samples of food for PFAS through TDS and targeted assignments and surveys. The FDA will continue to pursue additional sampling to better understand PFAS in the U.S. food supply. Changes to the PFAS Website First, to improve transparency and provide greater context about our analytical findings, we have updated our reporting to include both Method Detection Limits (MDL) and Limits of Quantification (LOQ), rather than relying solely on MDL values. Results are now categorized as follows: Below MDL: Not detected Above MDL but below LOQ: Trace levels reported in italics Above LOQ: Quantifiable levels reported Second, we are now including an additional toxicological reference value for assessing the safety of perfluorodecanoic acid (PFDA) levels found in food. Future PFAS Testing The FDA will continue to analyze TDS samples for PFAS with the goal of estimating U.S. consumers’ dietary PFAS exposure to help inform FDA’s activities to reduce PFAS levels in food. Testing will analyze a wide array of foods through TDS, including bread and grains; fruits and vegetables; meat, eggs, and dairy products, including milk; and seafood. The FDA will continue to work closely with our federal partners and state departments of agriculture and health to share information and enhance collaboration in our efforts to gather a more robust dataset of PFAS in foods as we work together to reduce the public’s dietary exposure to PFAS.

PTEN Deficiency in Prostate Cancer: Biology, Prognosis, and Therapeutic Relevance Authors: Elena Castro, MD, PhD

https://www.medscape.org/viewarticle/pten-deficiency-prostate-cancer-biology-prognosis-and-2025a1000rqh?page=1&sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251219-OUS-HONC-pten-deficiency-prostate-cancer-biology-prognosis-and-2025a1000rqh-cta

AI May Change How We Find Cancer

https://mydigitalpublication.com/publication/?i=857572&p=18&view=issueViewer&_hsenc=p2ANqtz-_xi3dqYrN2erjE2lxMMJWGcXeioEIXZbR-964xqT0S_4GSuZNfqz5tYY8LWcGMxTzZZEQ-dFtKYz2ODPPXphrzPJF2l21fBfW30xTdpDxKJ_lu4Sc&bt_field_name[]=utm_campaign&bt_field_name[]=utm_source&bt_field_name[]=utm_medium&bt_field_name[]=utm_content&bt_field_value[]=DDN_Newsletter_Monthly&bt_field_value[]=hs_email&bt_field_value[]=email&bt_field_value[]=2&utm_campaign=DDN_Newsletter_Monthly&utm_content=2&utm_medium=email&utm_source=hs_email Rather than replacing radiologists, AI is working alongside them to catch cancers earlier and improve screening efficiency.

Beyond Weight Loss: GLP-1s Show Promise in Breast Cancer Megan Brooks December 18, 2025 +++ +++

https://www.medscape.com/viewarticle/beyond-weight-loss-glp-1s-show-promise-breast-cancer-2025a1000zlz N-AVD, BrECADD Win in Advanced Hodgkin Lymphoma Trials Randy Dotinga https://www.medscape.com/viewarticle/n-avd-brecadd-win-advanced-hodgkin-lymphoma-trials-2025a1000ztn December 19, 2025 Relapsed or Refractory Follicular Lymphoma Standard of Care Could Change Randy Dotinga https://www.medscape.com/viewarticle/relapsed-or-refractory-follicular-lymphoma-standard-care-2025a1000zt6 December 19, 2025 FDA OKs Subcutaneous Amivantamab for EGFR-Mutated NSCLC M. Alexander Otto, PA, MMSc https://www.medscape.com/viewarticle/fda-oks-subcutaneous-amivantamab-egfr-mutated-nsclc-2025a1000zrv December 19, 2025 Risk Score Predicts Pancreatic NET Recurrence Edited by Amy Norton https://www.medscape.com/viewarticle/risk-score-predicts-pancreatic-net-recurrence-2025a1000zru December 19, 2025 San Antonio Breast Cancer Symposium (SABCS) 2025 https://www.medscape.com/viewcollection/37937

Optimizing Outcomes for Thyroid Cancer With NTRK Gene Fusions: Precision Care, Patient Impact Authors: Jaume Capdevila, MD, PhD; Gary Bloom; Umberto Malapelle, PhD; Lori J. Wirth, MD

https://www.medscape.org/viewarticle/1002660?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251219-OUS-HONC-1002660-cta

Personalizing Relapsed/Refractory DLBCL With Bispecific Antibody Therapy: A Case-Based Discussion Authors: Joshua Brody, MD; Liz Brém, MD; Lorna Warwick

https://www.medscape.org/viewarticle/personalizing-relapsed-refractory-dlbcl-bispecific-antibody-2025a1000zir

Highlights From the Annual Neuro-Oncology Conference: Integrating IDH Inhibitor Therapy Into Glioma Care Authors: Maciej Mrugala, MD, PhD, MPH; Rimas V. Lukas, MD; Yoshie Umemura, MD

https://www.medscape.org/viewarticle/1003175

Acute Hepatic Porphyria: Bridging Gaps for Better Diagnosis and Management Authors: Brendan M. McGuire, MD, MS; Rebecca Karp, MD; Akshata Moghe, MD, PhD

https://www.medscape.org/viewarticle/acute-hepatic-porphyria-bridging-gaps-better-diagnosis-and-2025a1000ziy?page=1

Navigating the Storm of Heavily Pretreated Multiple Myeloma: Calming the Waters With Bispecific Antibodies Authors: Hermann C. Einsele, MD, PhD; Xavier Leleu, MD, PhD; Naresh Bumma, MD

https://www.medscape.org/viewarticle/1002692?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251220-OUS-HONC-1002692-cta

Are blood pressure disparities affecting mortality (Medscape AI) +... +++ ++ +++

Racial and other disparities in blood pressure (BP) control contribute substantially to differences in cardiovascular and all-cause mortality. https://www.medscape.com/ai-search?query=Are%20blood%20pressure%20disparities%20affecting%20mortality&ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 INEQUITIES IN CLINICAL OUTCOMES Hidden ECG Patterns Reveal Race & Wealth Links AI Model Can Distinguish Race From ECG Readings in People With Higher Socioeconomic Status Brian Owens https://www.medscape.com/viewarticle/ai-model-can-distinguish-race-ecg-readings-people-higher-2025a1000rvo?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 October 16, 2025 Steeper Survival Odds in These Patients AML: Clinical Data Confirms Lower Survival in Black Patients Randy Dotinga https://www.medscape.com/viewarticle/aml-clinical-data-confirms-lower-survival-black-patients-2025a1000y86?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 December 07, 2025 Unspoken Bias Changing How Patients Are Treated Weight Bias in the Hospital: Implicit Attitudes Shape Care Julie Peck https://www.medscape.com/viewarticle/weight-bias-hospital-implicit-attitudes-shape-care-2025a1000xmt?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 December 02, 2025 TECH & ACCESS BIASES Are Subjective Scores Blocking Progress? Bias, Subjective Outcomes Slow AI Advances in Dermatology Marcia Frellick https://www.medscape.com/viewarticle/bias-subjective-outcomes-slow-ai-advances-dermatology-2025a1000w0y?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 November 18, 2025 STI Testing Falls Short for Certain Communities Low Rates Seen With Packaged STI Testing, With Substantial Racial, Ethnic, Age, and Insurance Status Disparities Tara Haelle https://www.medscape.com/viewarticle/low-rates-seen-packaged-sti-testing-substantial-racial-2025a1000u49?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 November 03, 2025 SOCIOECONOMIC DIVIDES New Self-Care Strategies Highlight Global Inequity Personalized Self-Management Empowers Patients With Chronic Respiratory Disease, but Global Inequities Persist Manuela Callari https://www.medscape.com/viewarticle/personalized-self-management-empowers-patients-chronic-2025a1000rxb?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 October 16, 2025 New Med School Initiative Transforms Local Care Rx for the Neighborhood: Community Medicine Programs in Med School Lambeth Hochwald https://www.medscape.com/viewarticle/rx-neighborhood-community-medicine-programs-med-school-2025a1000so2?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 October 22, 2025 Overlooked Signs Putting Patients at Risk Barriers to Timely Melanoma Diagnoses for Latino Patients: Study Points to Solutions Jennifer Lightowler, MMSc, PA-C https://www.medscape.com/viewarticle/barriers-timely-melanoma-diagnoses-latino-patients-study-2025a1000rc8?ecd=mkm_ret_251219_mscpmrk_broad_disparity_etid7967633&uac=148436CN&impID=7967633 October 10, 2025

Is Dark Skin the Blind Spot of Dermatology? ++++ +++ +++

TRENDING Is Dark Skin the Blind Spot of Dermatology? Is Dark Skin the Blind Spot of Dermatology? Carolin Hellerich https://www.medscape.com/viewarticle/dark-skin-blind-spot-dermatology-2025a1000y38?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 Medscape Europe December 05, 2025 Vitamin D: 4 Things You May Not Know Vitamin D: 4 Things You May Not Know David Warmflash, MD https://www.medscape.com/viewarticle/vitamin-d-4-things-you-may-not-know-2025a1000yhi?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 December 09, 2025 Inflammation Pursued as Target to Slow Skin Aging As a Key Driver, Inflammation Considered a Key Target for Anti-Skin-Aging Rxs Ted Bosworth https://www.medscape.com/viewarticle/key-driver-inflammation-considered-key-target-anti-skin-2025a1000z29?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 December 15, 2025 Do Doctors Consider Long-Term Effects in Psoriasis Care? Are Healthcare Professionals Considering Long-Term Effects When Managing Patients With Psoriasis? Edited by Vineeta Teotia https://www.medscape.com/viewarticle/are-healthcare-professionals-considering-long-term-effects-2025a1000xoq?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 ROSACEA Rosacea Underdiagnosed in This Cohort Rosacea Underdiagnosed in the Older Population: Look Beyond ‘Normal Skin Aging’ John Jesitus https://www.medscape.com/viewarticle/rosacea-underdiagnosed-older-population-look-beyond-normal-2025a1000w7e?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 November 19, 2025 Beyond Skin: How to Diagnose Ocular Rosacea Ocular Rosacea Underappreciated in Dermatology and Beyond John Jesitus https://www.medscape.com/viewarticle/ocular-rosacea-underappreciated-dermatology-and-beyond-2025a1000u9h?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 November 04, 2025 Does Vagus Nerve Therapy Improve Rosacea? Vagus Nerve Therapy Improved Rosacea Symptoms, Study Finds Edited by Deepa Varma https://www.medscape.com/viewarticle/vagus-nerve-therapy-improved-rosacea-symptoms-study-finds-2025a1000r2y?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 October 08, 2025 ATOPIC DERMATITIS Biologic Super Response Predicts Sustained Benefit Super Response to Biologics for Skin Diseases Often Predicts Sustained Benefit Ted Bosworth https://www.medscape.com/viewarticle/super-response-biologics-skin-diseases-often-predicts-2025a1000qkk?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 October 03, 2025 Higher Surgical Risks for Atopic Patients Atopic Conditions Linked to More Surgical Complications After Breast Reconstruction and Bone Grafting, Studies Find Lara Salahi https://www.medscape.com/viewarticle/atopic-conditions-linked-more-surgical-complications-after-2025a1000v2k?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 November 10, 2025 Broad Anti-Eczema Effects Seen With IL-22 Inhibitor Interleukin-22 Inhibitor Provides Broad Activity Against AD Biomarkers Ted Bosworth https://www.medscape.com/viewarticle/interleukin-22-inhibitor-provides-broad-activity-against-ad-2025a1000yw9?ecd=mkm_ret_251218_mscpmrk_derm_skin-disorders_etid7963642&uac=148436CN&impID=7963642 December 12, 2025

Phase 3 Data of Vonvendi for the Treatment of Von Willebrand Disease By: Madaline Spencer| Published on: Dec 19, 2025

https://checkrare.com/phase-3-data-of-vonvendi-for-the-treatment-of-von-willebrand-disease/ Latest Summaries https://checkrare.com/

RARE DISEASE LEARNING CENTERS +++++

CME PROGRAMS Immune Thrombotic Thrombocytopenic Purpura (iTTP) Clinical Research Highlights: ISTH 2025 https://checkrare.com/learning/p-isth2025-module3-immune-thrombotic-thrombocytopenic-purpura-ittp-clinical-research-highlights/ Shruti Chaturvedi, MD, provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with iTTP. CREDITS: 0.5 CME | DURATION: 30 minutes EXPIRES: 9/15/2026 | FEE: $0 Immune Thrombocytopenia Clinical Research Highlights: ISTH 2025 https://checkrare.com/learning/p-isth2025-module2-immune-thrombocytopenia-clinical-research-highlights/ Shruti Chaturvedi, MD, provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with ITP. CREDITS: 0.5 CME | DURATION: 30 minutes EXPIRES: 9/15/2026 | FEE: $0 Hemophilia Clinical Research Highlights: ISTH 2025 https://checkrare.com/learning/p-isth2025-module1-hemophilia-clinical-research-highlights/ Steven Pipe, MD, provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with hemophilia. CREDITS: 0.75 CME | DURATION: 45 minutes EXPIRES: 9/15/2026 | FEE: $0 RARE DISEASE LEARNING CENTERS Cutaneous T-Cell Lymphoma (CTCL) https://checkrare.com/cutaneous-t-cell-lymphoma-2/ Cutaneous T-cell lymphoma (CTCL) belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders. WHIM Syndrome https://checkrare.com/whim-syndrome/ WHIM syndrome is a rare, congenital primary immunodeficiency disorder associated with neutropenia that typically presents in childhood or adolescence.

FDA NEWS & CLINICAL PERSPECTIVES ++++ +++++

FDA NEWS 2025 Orphan Drugs: PDUFA Dates and FDA Approvals https://checkrare.com/2025-orphan-drugs-pdufa-dates-and-fda-approvals/ Rare diseases and orphan drugs are at the forefront of novel development and groundbreaking research. Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory dates for all orphan drugs for 2025. FDA Approves Ziftomenib for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia https://checkrare.com/fda-approves-ziftomenib-for-relapsed-refractory-npm1-mutated-acute-myeloid-leukemia/ The U.S. FDA has approved Komzifti (ziftomenib) for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with susceptible NPM1 mutation. Darzalex Faspro for Patients With High-Risk Smoldering Multiple Myeloma https://checkrare.com/fda-approves-darzalex-faspro-for-patients-with-high-risk-smoldering-multiple-myeloma/ The U.S. FDA has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). FDA Approves Revumenib for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia https://checkrare.com/fda-approves-revumenib-for-the-treatment-of-relapsed-refractory-acute-myeloid-leukemia/ The U.S. FDA has approved Revuforj (revumenib) for the treatment of relapsed/refractory acute myeloid leukemia (AML). CLINICAL PERSPECTIVES Long-Term Data From the AQUARIUS Study of Avacopan in Patients With GPA and MPA https://checkrare.com/long-term-data-from-the-aquarius-study-of-avacopan-in-patients-with-gpa-and-mpa/ Naomi Patel, MD, MPH, Rheumatologist at Massachusetts General Hospital, discusses long-term data from the AQUARIUS study of avacopan in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Hemolytic Disease of the Fetus and Newborn: Outcomes of Intrauterine Transfusion and Patient Experiences https://checkrare.com/hemolytic-disease-of-the-fetus-and-newborn-outcomes-of-intrauterine-transfusion-and-patient-experiences/ May Lee Tjoa, PhD, Senior Global Medical Affairs Leader: Nipocalimab and Maternal-Fetal Immunology at Johnson & Johnson, discusses data on hemolytic disease of the fetus and newborn (HDFN) from the 2025 ISUOG World Congress on Ultrasound in Obstetrics and Gynecology. Rilzabrutinib Approval for Adult Patients With Immune Thrombocytopenia https://checkrare.com/rilzabrutinib-approval-for-adult-patients-with-immune-thrombocytopenia/ Amit Mehta, MD, Medical Oncologist, discusses data that led to the approval of Wayrilz (rilzabrutinib) for adult patients with immune thrombocytopenia (ITP). ISUOG World Congress 2025: Hemolytic Disease of the Fetus and Newborn https://checkrare.com/isuog-world-congress-2025-hemolytic-disease-of-the-fetus-and-newborn/ Jannine Williams, Compound Development Team Leader at Johnson & Johnson, discusses key takeaways from studies on hemolytic disease of the fetus and newborn (HDFN) presented at ISUOG World Congress 2025. Plans for Phase 2/3 Clinical Trial of Bexmarilimab Plus Standard of Care in Patients With Myelodysplastic Syndromes https://checkrare.com/plans-for-phase-2-3-clinical-trial-of-bexmarilimab-plus-standard-of-care-in-patients-with-myelodysplastic-syndromes/ Amer Zeidan, MBBS, MHS, Professor of Internal Medicine at Yale School of Medicine and Chief of the Division of Hematologic Malignancies at Yale Cancer Center, discusses plans for a phase 2/3 clinical trial testing bexmarilimab plus standard of care in patients with myelodysplastic syndromes (MDS).

Rare Disease Focus: Hematologic Disorders +++++

FEATURED ARTICLES Survey Finds Wide-Ranging Impact of X-Linked Hypophosphatemia (XLH) on Patient Experiences https://checkrare.com/survey-finds-wide-ranging-impact-of-x-linked-hypophosphatemia-on-patient-experiences/ Al Freedman, PhD, Rare Disease Psychologist and Rare Dad, and Jill H. Simmons, MD, Endocrinologist at Vanderbilt University Medical Center in Nashville, Tennessee highlight the burden of XLH on personal finances and out-of-pocket costs, overall health—physical, mental, and social—and access to expert care. New Staging Tool Available for Healthcare Providers Treating Patients With CTCL https://checkrare.com/new-staging-tool-available-for-healthcare-providers-treating-patients-with-ctcl/ Pamela Blair Allen, MD, MSc, Hematologist, discusses the new CTCL Staging Tool on PROBEinCTCL.com. Chronic Myeloid Leukemia: Overview, Treatment Options, and Advice for Newly Diagnosed Patients https://checkrare.com/chronic-myeloid-leukemia-overview-treatment-options-and-advice/ Jorge Cortes, MD, Director of the Georgia Cancer Center, provides an overview of chronic myeloid leukemia (CML), discusses treatment options, and offers advice to newly diagnosed patients. Cutaneous T-Cell Lymphoma: Natural History and the Need for Better Diagnostic and Treatment Efficacy https://checkrare.com/cutaneous-t-cell-lymphoma-natural-history-and-the-need-for-better-diagnostic-and-treatment-efficacy/ Henry Wong, MD, PhD, Dermatologist at the San Diego Veterans Hospital and the University of California San Diego (UCSD), discusses cutaneous T-cell lymphoma (CTCL). Chronic Myeloid Leukemia: Diagnosis and Treatment https://checkrare.com/chronic-myeloid-leukemia-diagnosis-and-treatment/ Michael Mauro, MD, Director of the Chronic Myeloid Leukemia Program at Memorial Sloan Kettering Cancer Center, discusses the diagnosis and treatment of chronic myeloid leukemia (CML).

Enhancing Impactful Patient-Centered Care for NMSC Through Meaningful Connections Authors: Dirk Schadendorf, MD; Emily Ruiz, MD, MPH

https://www.medscape.org/viewarticle/1002953?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251218-OUS-HONC-1002953-cta

Addressing Challenges for Patients With HR+/HER2- EBC: Managing AEs and Optimizing Adherence Authors: Sarah Donahue, MPH, NP, AOCNP; Erika Hamilton, MD; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/1002936?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251218-OUS-HONC-1002936-cta

Advancing Treatment for HER2-Positive Advanced Breast Cancer: Expert Analysis of the Latest Developments Authors: Judy King, MRCP, PhD; Peter Fasching, MD

https://www.medscape.org/viewarticle/1002765?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251218-OUS-HONC-1002765-cta

Under the Skin: Revolutionizing Immunotherapy Delivery in Lung Cancer Authors: Sanjay Popat, PhD, FRCP; Alba Silverio Pons, RN; Alba Manzaneque, BCOP; Debra Montague

https://www.medscape.org/viewarticle/1002630?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251219-OUS-HONC-1002630-cta

One Team, One Goal: The Key to Better Patient Outcomes in Early Breast Cancer Management Authors: Fatima Cardoso, MD, FESMO, ESCO; Nadia Harbeck, MD, PhD; Shani Paluch, MBBS, MSc

https://www.medscape.org/viewarticle/1002593

Multiorgan Fibroinflammatory Challenges in Multidisciplinary Practice: What's Your Approach? Authors: Emma Culver, MD, PhD

https://www.medscape.org/viewarticle/multiorgan-fibroinflammatory-challenges-multidisciplinary-2025a1000npv?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251217-OUS-HONC-multiorgan-fibroinflammatory-challenges-multidisciplinary-2025a1000npv-cta

A key to long-term HIV control

https://www.nih.gov/news-events/nih-research-matters/key-long-term-hiv-control

Arsenic reduction linked to lower risk of death

https://www.nih.gov/news-events/nih-research-matters/arsenic-reduction-linked-lower-risk-death

Difference in kidney function tests predicts health risks

https://www.nih.gov/news-events/nih-research-matters/difference-kidney-function-tests-predicts-health-risks

Colonoscopy Delay Up to 24 Months After Positive FIT Not Tied to Added CRC Risk Edited by Archita Rai December 18, 2025

https://www.medscape.com/viewarticle/colonoscopy-delay-24-months-after-positive-fit-not-tied-2025a1000zlt

Antibiotics Up Risk for Skin Events in Cancer Immunotherapy Edited by Gargi Mukherjee December 18, 2025

https://www.medscape.com/viewarticle/antibiotics-risk-skin-events-cancer-immunotherapy-2025a1000zjt

Giredestrant for Early Breast Cancer: Where Will It Fit In? Alan Mozes December 18, 2025

https://www.medscape.com/viewarticle/giredestrant-early-breast-cancer-where-will-it-fit-2025a1000znd

FDA Says It Will Act Quickly to Approve New Sunscreen Ingredient Alicia Ault December 18, 2025

https://www.medscape.com/viewarticle/fda-says-it-will-act-quickly-approve-new-sunscreen-2025a1000znz

An Expert Discussion of Key New Data in CLL and MCL: How May It Impact Future Practice? Authors: Paolo Ghia, MD, PhD; Kami Maddocks, MD

https://www.medscape.org/viewarticle/expert-discussion-key-new-data-cll-and-mcl-how-may-it-impact-2025a1000pm5?sso=true&uac=148436CN&src=mkmcmr_driv_32025_mscpedu_421115.13_ace_launch

Medscape Now! Navigating the High-Fiber Trend of Fibermaxxing: Benefits, Risks, and Clinical Guidance Authors: CME Author: Naseem Bazargan, MPH

https://www.medscape.org/viewarticle/medscape-now-navigating-high-fiber-trend-fibermaxxing-2025a1000yty?page=1

Navigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy Authors: David S. Hong, MD; Theodore W. Laetsch, MD; Jonathan C. Trent, MD, PhD

https://www.medscape.org/viewarticle/navigating-advances-trk-fusion-positive-cancers-2025a1000z5i?page=1

Immunotherapy in Early-Stage Cancers: Multidisciplinary Team Best Practices Authors: Nadia Harbeck, MD, PhD; Enriqueta Felip, MD; Elizabeth Mittendorf, MD; Suresh Senan, MD

https://www.medscape.org/viewarticle/1002762?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251217-OUS-HONC-1002762-cta

Hirsutism and Hyperandrogenism (PCDS)

Hirsutism and Hyperandrogenism (PCDS) Hirsutism and Hyperandrogenism Source: Primary Care Dermatology Society This Medscape guideline summary combines information from the PCDS on hirsutism and hyperandrogenism, covering clinical features, investigations, and management of the conditions. Refer to the original guidelines for clinical images. •Investigating excess hair growth https://reference.medscape.com/cc2/p10/hirsutism-and-hyperandrogenism-2025a1000cwb?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#1 •Hyperandrogenism key causes https://reference.medscape.com/cc2/p10/hirsutism-and-hyperandrogenism-2025a1000cwb?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#1 •PCOS: when to check labs https://reference.medscape.com/cc2/p10/hirsutism-and-hyperandrogenism-2025a1000cwb?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#1

Vitamin B12 Deficiency (NICE)

Vitamin B12 Deficiency (NICE) Vitamin B12 Deficiency in Over 16s: Diagnosis and Management Source: National Institute for Health and Care Excellence This Medscape guideline summary covers recognising, diagnosing, and managing vitamin B12 deficiency in people aged 16 and over. It also covers monitoring for gastric cancer in people with autoimmune gastritis caused by vitamin B12 deficiency. For recommendations on information and support, identifying the cause of vitamin B12 deficiency, and self-administration, refer to the full guideline. •Key risk factors https://reference.medscape.com/cc2/p10/vitamin-b12-deficiency-over-16s-diagnosis-and-management-2024a10003wa?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681 •Total B12 vs active B12 https://reference.medscape.com/cc2/p10/vitamin-b12-deficiency-over-16s-diagnosis-and-management-2024a10003wa?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681 •When to test https://reference.medscape.com/cc2/p10/vitamin-b12-deficiency-over-16s-diagnosis-and-management-2024a10003wa?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681

Adrenal Insufficiency (NICE)

Adrenal Insufficiency: Identification and Management Source: National Institute for Health and Care Excellence This guideline summary covers the identification and management of adrenal insufficiency (hypoadrenalism) in general practice. Recommendations concern primary, secondary, and tertiary adrenal insufficiency. Guidance on managing glucocorticoid withdrawal to prevent adrenal insufficiency is included. Adrenal Insufficiency (NICE) •Initial investigations https://reference.medscape.com/cc2/p10/adrenal-insufficiency-identification-and-management-2024a1000f5k?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681 •Replacement therapy https://reference.medscape.com/cc2/p10/adrenal-insufficiency-identification-and-management-2024a1000f5k?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681 •Recognizing adrenal crisis https://reference.medscape.com/cc2/p10/adrenal-insufficiency-identification-and-management-2024a1000f5k?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681

Thyroid Disease (NICE)

Thyroid Disease (NICE) Thyroid Disease: Assessment and Management Source: National Institute for Health and Care Excellence October 2023: In the section on investigating suspected thyroid dysfunction, NICE added a new recommendation on the potential for biotin to interfere with the results of thyroid function tests. The team added the section Managing and monitoring subclinical hypothyroidism, and information on antithyroid drugs for adults, children, and young people with hyperthyroidism in the section Managing thyrotoxicosis. •When to test beyond symptoms https://reference.medscape.com/cc2/p10/thyroid-disease-assessment-and-management-2022a100124a?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#12 •Levothyroxine initial dosing https://reference.medscape.com/cc2/p10/thyroid-disease-assessment-and-management-2022a100124a?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#12 •TSH monitoring frequency https://reference.medscape.com/cc2/p10/thyroid-disease-assessment-and-management-2022a100124a?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#12

What Do Primary Care Practitioners Need to Know About Weight-loss Medications? Dr Pam Brown offers practical information for general practitioners on the safe prescribing of liraglutide, semaglutide, and tirzepatide for weight loss Dr Pam Brown

https://reference.medscape.com/cc1/p10/what-do-primary-care-practitioners-need-know-about-weight-2025a10006lb?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681 Obesity (EASD) Diagnosis, Staging, and Management of Obesity in Adults Source: European Association for the Study of Obesity; Medically Reviewed by Dr Kevin Fernando In 2024, the European Association for the Study of Obesity (EASO) published a proposed framework for future guidance on the diagnosis, staging, and management of obesity in adults.[1] This Medscape guideline summary for general practitioners highlights the need for updated guidance on obesity, emphasising its nature as a chronic disease and the limitations of using body mass index (BMI) as the sole diagnostic criterion. With reference to other UK guidance on the management of obesity,[2][3] this summary examines the EASO's recommendations on diagnosis based on anthropometric and clinical components, staging of obesity according to severity, and approaches to management including behavioural modifications, pharmacological treatments, and surgical procedures. •Adipose tissue distribution implications https://reference.medscape.com/cc2/p10/guideline-essentials-2024-european-association-study-obesity-2024a1000mk0?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#1 •Refined crtieria for medical management https://reference.medscape.com/cc2/p10/guideline-essentials-2024-european-association-study-obesity-2024a1000mk0?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#1 •Behavior modification recommendations https://reference.medscape.com/cc2/p10/guideline-essentials-2024-european-association-study-obesity-2024a1000mk0?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#1

Key Learning Points: NICE Adrenal Insufficiency Dr Kevin Fernando provides six key learning points on the identification and management of adrenal insufficiency in primary care based on NICE Guideline 243 Dr Kevin Fernando

https://reference.medscape.com/cc1/p10/key-learning-points-nice-adrenal-insufficiency-2025a10008tk?sso=true&uac=148436CN&ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&impID=7963681

Diabetes Identification (ADA) - Diabetes Prevention and Management (ADA)

Diabetes Identification (ADA) Standards of Care in Diabetes—Part 1: Summary for General Practice Source: American Diabetes Association; Medically Reviewed by Dr Roger Henderson The American Diabetes Association (ADA) has updated its guidance on standards of care in diabetes for 2025.[1] This guideline overview for GPs, the first in a series on this comprehensive guideline, focuses on the clinical presentation, classification, identification, and diagnosis of diabetes with reference to other key guidance on diabetes management. The recommendations cover the management of type 1 diabetes, type 2 diabetes, gestational diabetes, and other forms of diabetes or hyperglycaemia in all age groups. •Characteristics of prediabetes https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-diabetes-association-2025a100074f?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681 •Screening with risk calculators https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-diabetes-association-2025a100074f?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#1 •Determining type and severity https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-diabetes-association-2025a100074f?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681#1 Diabetes Prevention and Management (ADA) Standards of Care in Diabetes—Part 2: Summary for General Practice Source: American Diabetes Association; Medically Reviewed by Dr Roger Henderson In 2024, the American Diabetes Association (ADA) published guidance on standards of care in diabetes.[1] This guideline overview, the second in a series, focuses on the prevention and management of diabetes and its complications in all age groups, with reference to other key guidance on diabetes management. •Type 1 vs type 2 prevention https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-diabetes-association-2025a1000an1?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681 •Optimal timing for T2D therapy https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-diabetes-association-2025a1000an1?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681 •Key T2D combo therapies https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-diabetes-association-2025a1000an1?ecd=WNL_drugguide_251218_MSCPREF_endo_etid7963681&uac=148436CN&impID=7963681

New clinical trial offers hope for patients with advanced “dry” age-related macular degeneration

https://www.news-medical.net/news/20251217/New-clinical-trial-offers-hope-for-patients-with-advanced-e2809cdrye2809d-age-related-macular-degeneration.aspx

Sitting harms blood vessel function, but cocoa flavanols can stop it

https://www.news-medical.net/news/20251217/Sitting-harms-blood-vessel-function-but-cocoa-flavanols-can-stop-it.aspx A simple cocoa-based intervention taken just before long periods of sitting can help preserve blood vessel function in both the arms and the legs. This highlights a practical nutritional strategy to counter the hidden cardiovascular risks of modern sedentary life.

Editorial e927 Acute myeloid leukaemia at the extremes The Lancet Haematology ++ +...

Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-8KGpoy87VI4ht9FYkINihi8PvuSRwkHWCVB3G75Ms9LnxUXLu7fG0wtuA1WLiBXtkOnWj4rImaLvzaCaNVLgE7NWsZ8Q&_hsmi=394395134&utm_content=393827040&utm_source=hs_email Motivators and barriers affecting decisions to participate in sickle cell disease clinical trials in the global Learning and Insights into Sickle Cell Trial Experiences (LISTEN) Survey: global and regional findings https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00295-9/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz--uO0YWGE69YvRfurJq8h-auWMBUoABX5SKuwQOWl8klgI_CeP54dTefS36F5f1aY3yQkpMkagDkis00W9HgNjRSDAvkA&_hsmi=394395134&utm_content=393827040&utm_source=hs_email Editorial e927 Acute myeloid leukaemia at the extremes The Lancet Haematology https://www.thelancet.com/journals/lanhae/issue/vol12no12/PIIS2352-3026(25)X0012-0

Advancing Treatment for HER2-Positive Advanced Breast Cancer: Expert Analysis of the Latest Developments Authors: Judy King, MRCP, PhD; Peter Fasching, MD

https://www.medscape.org/viewarticle/1002765?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251215-OUS-HONC-1002765-cta

Navigating the Storm of Heavily Pretreated Multiple Myeloma: Calming the Waters With Bispecific Antibodies Authors: Hermann C. Einsele, MD, PhD; Xavier Leleu, MD, PhD; Naresh Bumma, MD

https://www.medscape.org/viewarticle/1002692?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251216-OUS-HONC-1002692-cta

Patients’ Insights Illuminated: A Rapid-Fire Dive Into CLL and MCL Authors: Lorna Warwick; Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD; Nicole Lamanna, MD; David Ball; Vivienne Ball

https://www.medscape.org/viewarticle/1002737?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251216-OUS-HONC-1002737-cta

Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer: Translating Science Into Clinical Practice Authors: Rahul Gosain, MD, MBA; Rohit Gosain, MD; David S. Hong, MD; Theodore W. Laetsch, MD; Jarushka Naidoo, MB, BCH, MHS

https://www.medscape.org/viewarticle/1002679?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251216-OUS-HONC-1002679-cta

Evidence and responsibility of artificial intelligence use in mental health care The Lancet Digital Health ++... ++

https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00141-4/fulltext?dgcid=raven_jbs_etoc_email Nov 2025 Volume 7Number 11 https://www.thelancet.com/journals/landig/issue/vol7no11/PIIS2589-7500(25)X0011-X Automated retinal image analysis systems to triage for grading of diabetic retinopathy: a large-scale, open-label, national screening programme in England https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00096-2/fulltext?dgcid=raven_jbs_etoc_feature_landig Artificial intelligence imaging decision support for acute stroke treatment in England: a prospective observational study https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00109-8/fulltext?dgcid=raven_jbs_etoc_feature_landig

A day in the life: reconciling grief and gratitude 17 December 2025

https://rarerevolutionmagazine.com/a-day-in-the-life-reconciling-grief-and-gratitude/ I wake before the sun most days—not because I want to, but because my body decides it’s time. Pain pulls me out of sleep before my mind has even caught up. I stretch carefully, the way you’d handle something fragile and cracked, always wondering if today will be the day a piece of me finally breaks.

Aducanumab: advancing Alzheimer’s treatment through regulation of excessive β-amyloid accumulation Clotilde Nsimire Katana Kachungunu [1] , Subhash Namdeo Mashal [1] , Priyadarshi Soumyaranjan Sahu* [1]

https://www.academia.edu/academia-immunity-and-disease/1/1/10.20935/AcadImmunoDis8055 Abstract Objective: Several drugs have been studied in past decades, with the main purpose of primarily being used for the symptomatic relief of Alzheimer’s Disease (AD). As of today, there are hundreds of ongoing studies to find a pharmacological treatment that will not only lessen the neurological symptoms of AD but will also slow down the progression or find a definite cure for the disease. We hypothesized that the emerging treatments for AD, such as Aducanumab, should primarily target the excessive brain accumulation of either β-amyloid peptides or tau proteins, thus delay the progression of illness when compared to the standard pharmacological treatment. The present systematic review explored and addressed Aducanumab therapy as an emerging treatment to cure, prevent, or slow down AD progression. Methods: A comprehensive literature search was conducted on PubMed using predefined search terms; the identified studies were then screened. Finally, 47 of the 210 articles were included for data extraction and analysis. Results: This study analyzed the validity and efficacy of Aducanumab. Aducanumab is a pharmacotherapy that targets excessive β-amyloid peptides in the brain; however, it does not have any role in reducing aggregated hyperphosphorylated tau proteins. Aducanumab has been analyzed and juxtaposed with the standard treatment, acetylcholinesterase inhibitors. Aducanumab is an effective pharmacotherapy that lowers β-amyloid peptides in the brain, and therefore, it helps treat AD. The side effects of Aducanumab are not deemed significant enough to justify FDA disapproval, and they can easily be monitored and prevented. Conclusions: Aducanumab has been proven to be a very effective and promising pharmacotherapy in treating AD. It is also the first disease-modifying pharmacotherapy for AD, and compared to the standard treatment, it is preferable in all aspects for slowing down or stopping the progression of AD.

Enhancing Impactful Patient-Centered Care for NMSC Through Meaningful Connections Authors: Dirk Schadendorf, MD; Emily Ruiz, MD, MPH

https://www.medscape.org/viewarticle/1002953?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251216-OUS-HONC-1002953-cta

Applying Guideline-Directed Systemic Therapy for Advanced Bladder Cancer Dr Jose Tapia discusses guideline recommendations for systemic treatment in bladder cancer, and assesses therapeutic developments that will further shape guidance and improve outcomes Dr Jose Tapia

Applying Guideline-Directed Systemic Therapy for Advanced Bladder Cancer Dr Jose Tapia discusses guideline recommendations for systemic treatment in bladder cancer, and assesses therapeutic developments that will further shape guidance and improve outcomes Dr Jose Tapia https://reference.medscape.com/cc1/p10/applying-guideline-directed-systemic-therapy-advanced-2025a1000lvm?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Top Tips: Metastatic Breast Cancer Dr Fharat Raja provides 10 top tips for oncologists on metastatic breast cancer, encompassing the latest UK, European, and US guidance Dr Fharat Raja

Top Tips: Metastatic Breast Cancer Dr Fharat Raja provides 10 top tips for oncologists on metastatic breast cancer, encompassing the latest UK, European, and US guidance Dr Fharat Raja https://reference.medscape.com/cc1/p10/top-tips-metastatic-breast-cancer-2025a1000dc0?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Metastatic Malignant Disease of Unknown Primary Origin in Adults: Diagnosis and Management Source: National Institute for Health and Care Excellence

Metastatic Malignant Disease of Unknown Primary Origin in Adults: Diagnosis and Management Source: National Institute for Health and Care Excellence Cancer of Unknown Primary (NICE) •Initial diagnostic steps https://reference.medscape.com/cc2/p10/metastatic-malignant-disease-unknown-primary-origin-adults-2023a1000fgz?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611#1 •When to use PET–CT scans https://reference.medscape.com/cc2/p10/metastatic-malignant-disease-unknown-primary-origin-adults-2023a1000fgz?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611#1

Bladder Cancer (ESMO) Source: European Society for Medical Oncology; Medically Reviewed by Professor Noel Clarke

Bladder Cancer (ESMO) Bladder Cancer Source: European Society for Medical Oncology; Medically Reviewed by Professor Noel Clarke •Imaging and cytoscopy https://reference.medscape.com/cc2/p10/guideline-essentials-2021-esmo-recommendations-bladder-2024a10003qf?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Augmented visualization for TURBT https://reference.medscape.com/cc2/p10/guideline-essentials-2021-esmo-recommendations-bladder-2024a10003qf?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Neoadjuvant chemotherapy for MIBC https://reference.medscape.com/cc2/p10/guideline-essentials-2021-esmo-recommendations-bladder-2024a10003qf?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Breast Cancer Germline Testing (ASCO) Source: American Society of Clinical Oncology, Society of Surgical Oncology; Medically Reviewed by Dr Fharat Raja

Breast Cancer Germline Testing (ASCO) Germline Testing in Breast Cancer Source: American Society of Clinical Oncology, Society of Surgical Oncology; Medically Reviewed by Dr Fharat Raja In 2024, the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) published a guideline on germline testing in breast cancer. This Medscape guideline summary covers BRCA1/2 testing for newly diagnosed patients, those with recurrent disease or second primaries, and those with personal history but no active disease, as well as the value of testing for other predisposition genes and genetic counselling. Please refer to the full ASCO–SSO guideline for all recommendations, rationale, and background information. •When to offer BRCA1/2 testing https://reference.medscape.com/cc2/p10/guideline-essentials-asco-sso-recommendations-germline-2025a10004h3?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Testing for stage I–IV disease https://reference.medscape.com/cc2/p10/guideline-essentials-asco-sso-recommendations-germline-2025a10004h3?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Recurrent cancer and PARP inhibitors https://reference.medscape.com/cc2/p10/guideline-essentials-asco-sso-recommendations-germline-2025a10004h3?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Palliative Care (ASCO) Source: American Society of Clinical Oncology; Medically Reviewed by Professor Graham Jackson

Palliative Care (ASCO) Palliative Care Integration in Cancer Care Source: American Society of Clinical Oncology; Medically Reviewed by Professor Graham Jackson In 2024, the American Society of Clinical Oncology (ASCO) published an updated guideline on palliative care for patients with cancer. This Medscape guideline summary for oncologists provides recommendations regarding optimal provision of palliative care services for patients with cancer and their caregivers, updating previous ASCO guidance from 2012 and 2016. The update aims to equip oncology professionals with current recommendations while evaluating the continued validity of previous guidance, and includes new discussions on integrating palliative care for patients with haematological malignancies and those enrolled in phase I clinical trials, as well as addressing health equity in oncology palliative care. •When to introduce palliative care https://reference.medscape.com/cc2/p10/guideline-essentials-asco-recommendations-palliative-care-2025a1000kwr?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Referral for poor-prognosis cancers https://reference.medscape.com/cc2/p10/guideline-essentials-asco-recommendations-palliative-care-2025a1000kwr?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Supporting caregiver needs https://reference.medscape.com/cc2/p10/guideline-essentials-asco-recommendations-palliative-care-2025a1000kwr?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Immunotherapy for Multiple Myeloma (IMWG) Source: International Myeloma Working Group Immunotherapy Committee

Immunotherapy for Multiple Myeloma (IMWG) Sequencing Immunotherapy for Multiple Myeloma Source: International Myeloma Working Group Immunotherapy Committee In 2025, the International Myeloma Working Group Immunotherapy Committee published a set of nine consensus recommendations for the optimal sequential use of immunotherapy agents in the treatment of multiple myeloma. These recommendations were developed by a panel of experts based on the current available evidence. •TCRT or CAR-T cell therapy https://reference.medscape.com/cc2/p10/sequencing-immunotherapy-multiple-myeloma-international-2025a10004pv?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •TCE for rapid progression https://reference.medscape.com/cc2/p10/sequencing-immunotherapy-multiple-myeloma-international-2025a10004pv?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Progressive MM alternatives https://reference.medscape.com/cc2/p10/sequencing-immunotherapy-multiple-myeloma-international-2025a10004pv?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Cancer Immunotherapy: Squamous Cell Carcinoma of the Head and Neck Source: Society for Immunotherapy of Cancer

Head and Neck SCC (SITC) Cancer Immunotherapy: Squamous Cell Carcinoma of the Head and Neck Source: Society for Immunotherapy of Cancer •Biomarker testing https://reference.medscape.com/cc2/p10/cancer-immunotherapy-squamous-cell-carcinoma-head-and-neck-2025a10004tm?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Immunotherapy strategies https://reference.medscape.com/cc2/p10/cancer-immunotherapy-squamous-cell-carcinoma-head-and-neck-2025a10004tm?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Evaluating treatment responses https://reference.medscape.com/cc2/p10/cancer-immunotherapy-squamous-cell-carcinoma-head-and-neck-2025a10004tm?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Testicular Cancer (EAU) Source: European Association of Urology

Testicular Cancer (EAU) Testicular Cancer Source: European Association of Urology •Tumor classification https://reference.medscape.com/cc2/p10/eau-guideline-testicular-cancer-2025a10004wn?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •CS I seminoma: surveillance vs carboplatin https://reference.medscape.com/cc2/p10/eau-guideline-testicular-cancer-2025a10004wn?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Testis-sparing surgery criterias https://reference.medscape.com/cc2/p10/eau-guideline-testicular-cancer-2025a10004wn?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611

Fructans and ATIs impact digestive health in beer

https://www.news-medical.net/news/20251216/Fructans-and-ATIs-impact-digestive-health-in-beer.aspx

A multi-gene mouse model reveals new mechanisms of Hirschsprung disease

https://www.news-medical.net/news/20251216/A-multi-gene-mouse-model-reveals-new-mechanisms-of-Hirschsprung-disease.aspx

How Artificial Food Coloring Affects Children's Behavior and Health

https://www.news-medical.net/health/How-Artificial-Food-Coloring-Affects-Children-Behavior-and-Health.aspx Synthetic food dyes are widely used in packaged foods and can disproportionately affect children due to higher relative intake and developmental vulnerability. Evidence from clinical trials, animal studies, and regulatory reviews links certain dyes to behavioral changes, allergic reactions, and emerging concerns involving the gut–brain axis.

How Mycotoxin Contamination in Food Impacts Human Health

https://www.news-medical.net/health/How-Mycotoxin-Contamination-in-Food-Impacts-Human-Health.aspx Mycotoxins are toxic fungal metabolites that contaminate staple foods across the supply chain, posing widespread risks to human health even at low exposure levels. This article explains how mycotoxins enter food, the diseases they cause, who is most vulnerable, and how contamination can be detected and prevented.

Improving mCRPC Outcomes Using Radiopharmaceuticals: Evidence to Implementation Authors: Rana R. McKay, MD, FASCO; Matthew R. Cooperberg, MD, MPH; Sean M. McBride, MD, MPH, MS

https://www.medscape.org/viewarticle/1003039_sidebar9?sso=true&uac=148436CN&src=mkmcmr_driv_il_mscpedu_251215-1003039_ES_HONC

FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive?utm_medium=email&utm_source=govdelivery

Managing Progression on Frontline Immunotherapy: A Multidisciplinary Case Approach In Metastatic Melanoma Authors: Gino K. In, MD, MPH; Sunandana Chandra, MD, MS; Robert J. Lewandowski, MD; Ali Rastegarpour, MD

https://www.medscape.org/viewarticle/1002675?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251215-OUS-HONC-1002675-cta

Optimizing Management of NF1-Associated Plexiform Neurofibromas: Expert Multidisciplinary Team Discussions Authors: Judith Eelloo, RGN, RSCN, MPhil; Darren Hargrave, MD; Zhichao Wang, MD, MPH; Kaleb Yohay, MD

https://www.medscape.org/viewarticle/optimizing-management-nf1-associated-plexiform-neurofibromas-2025a1000rv5?sso=true&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_251215-OUS-HONC-optimizing-management-nf1-associated-plexiform-neurofibromas-2025a1000rv5-cta

FDA Approves Drug for Type of Abnormally Fast Heart Rhythm

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218571s000lbl.pdf?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration (FDA) has approved Cardamyst (etripamil) nasal spray to treat episodes of paroxysmal supraventricular tachycardia (PSVT), a condition where the heart beats abnormally fast. Disease or Condition People with paroxysmal supraventricular tachycardia (PSVT) have episodes in which their heart beats very fast, over 100 beats per minute. Symptoms can include heart palpitations, chest discomfort, shortness of breath, dizziness or lightheadedness, and fainting. PSVT occurs when a short circuit rhythm develops in the heart’s upper chamber. Symptoms persist until the normal heart rhythm is restored. Rarely, PSVT can damage the heart if it occurs often, leading to dilated cardiomyopathy. Data Supporting Cardamyst The safety and efficacy of Cardamyst were evaluated in the RAPID study (NCT #03464019), a double-blind, placebo-controlled phase 3 study in which 692 patients were randomly assigned to receive Cardamyst 70 mg or a placebo. Patients with an episode of perceived PSVT self-administered one dose of the drug and self-administered a second dose if symptoms persisted 10 minutes after the first dose. The primary endpoint was time it took for the abnormal heart rhythm to return to normal and stay normal for at least 30 seconds. Results showed that 64% and 31% of patients receiving Cardamyst and placebo, respectively, returned to normal heart rhythms within 30 minutes. The median (midpoint) time it took to return to normal was approximately 17 minutes for patients taking Cardamyst compared with 54 minutes for patients taking the placebo. Safety Information The most common side effects with Cardamyst are nasal discomfort, nasal congestion, runny nose, throat irritation, and nose bleeds. Patients with a hypersensitivity to Cardamyst or its components, heart failure, or certain other pre-conditions should not take Cardamyst. The medication may cause dizziness or fainting, so people should administer Cardamyst in a sitting position.

Targeting viral entry to expand antiviral drug discovery strategies

Targeting viral entry to expand antiviral drug discovery strategies New study uses simulations and machine learning to identify a single, high-impact interaction within a viral fusion protein, highlighting a potential new target for antiviral drug development. https://www.drugdiscoverynews.com/targeting-viral-entry-to-expand-antiviral-drug-discovery-strategies-16902

Articles on Neurology // Calculators

https://emedicine.medscape.com/neurology?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 Calculators https://reference.medscape.com/guide/medical-calculators?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

Top Tips: Care for Women with Fatigue and/or Chronic Pain

Top Tips: Care for Women with Fatigue and/or Chronic Pain Dr Louise Newson, Professor Deepak Ravindran, Dr Sarah Glynne, and Dr Ellen Fallows offer 10 top tips for primary care practitioners on improving care for women with fatigue and/or pain Dr Louise Newson, Prof Deepak Ravindran, Dr Sarah Glynne, Dr Ellen Fallows https://reference.medscape.com/cc1/p10/top-tips-care-women-fatigue-and-or-chronic-pain-2024a10009vj?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 Read This Article to Learn More About: fatigue, chronic pain, and the conditions commonly associated with these symptoms ways to improve the assessment and management of these symptoms in primary care potential benefits of lifestyle changes and hormone-replacement therapy including testosterone for women experiencing these symptoms. Implementation actions for integrated care systems can be found at the end of this article.

Adopt an Anticipatory and Multifaceted Approach to Dementia in Primary Care

Adopt an Anticipatory and Multifaceted Approach to Dementia in Primary Care Dr Sigi Joseph reviews the latest SIGN guidance on dementia, highlighting the key recommendations for implementation in general practice Dr Sigi Joseph https://reference.medscape.com/cc1/p10/adopt-anticipatory-and-multifaceted-approach-dementia-2024a1000iza?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 Read This Article to Learn More About: the diagnosis and classification of dementia anticipatory care planning and early, postdiagnostic support for people with dementia and their carers the role of general practice in ongoing support, medications management, treatment of comorbidities, and end-of-life care.

INSOMNIA (Riemann et al.)

INSOMNIA (Riemann et al.) Diagnosis and Treatment of Insomnia Source: Riemann D, Espie C, Altena E et al This Medscape summary covers recommendations from the updated European Insomnia Guideline on the diagnosis and management of insomnia, and includes a useful therapeutic algorithm as a guide for treatment. •ICSD-3 and ICD-11 criteria https://reference.medscape.com/cc2/p10/updated-european-insomnia-guideline-diagnosis-and-treatment-2024a1000ga9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •Drug treatment classes https://reference.medscape.com/cc2/p10/updated-european-insomnia-guideline-diagnosis-and-treatment-2024a1000ga9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •Nonpharmacological treatments https://reference.medscape.com/cc2/p10/updated-european-insomnia-guideline-diagnosis-and-treatment-2024a1000ga9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

TRIGEMINAL NEURALGIA (Lambru et al.)

TRIGEMINAL NEURALGIA (Lambru et al.) Trigeminal Neuralgia: A Practical Guide Source: Lambru G, Zakrzewski J, and Matharu M This Medscape guideline summary of Trigeminal neuralgia: a practical guide covers the diagnosis, clinical features, investigations, differential diagnosis, and treatment of trigeminal neuralgia (TN). For information on pathophysiology, acute treatment for severe exacerbation, surgical treatments, and other considerations, refer to the full practical guide. •The 3 TN subgroups https://reference.medscape.com/cc2/p10/trigeminal-neuralgia-practical-guide-2023a1000861?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •The role of MRI in workup https://reference.medscape.com/cc2/p10/trigeminal-neuralgia-practical-guide-2023a1000861?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •First-line treatment options https://reference.medscape.com/cc2/p10/trigeminal-neuralgia-practical-guide-2023a1000861?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

LOW BACK PAIN (WHO)

LOW BACK PAIN (WHO) Non-Surgical Management of Chronic Primary Low Back Pain in Adults in Primary and Community Care Settings Source: World Health Organization This is a Medscape summary of the World Health Organization’s guidance on managing chronic primary low back pain (CPLBP) in adults. Recommendations included cover education and advice, physical and psychological interventions, and medicines. •Tailored exercise programs https://reference.medscape.com/cc2/p10/who-guideline-non-surgical-management-chronic-primary-low-2024a100016w?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •Short-term pain relief https://reference.medscape.com/cc2/p10/who-guideline-non-surgical-management-chronic-primary-low-2024a100016w?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •When to prescribe NSAIDs https://reference.medscape.com/cc2/p10/who-guideline-non-surgical-management-chronic-primary-low-2024a100016w?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

RESTLESS LEGS SYNDROME (AASM)

RESTLESS LEGS SYNDROME (AASM) Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder Source: American Academy of Sleep Medicine; Medically Reviewed by Dr Roger Henderson •Essential iron studies https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-academy-sleep-medicine-2025a10004x9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 In 2025, the American Academy of Sleep Medicine (AASM) published a guideline on the treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD).[1] This Medscape overview for general practitioners examines the AASM recommendations on diagnosis, management, and follow up of RLS and PLMD, covering clinical presentation, investigations, and pharmacological and nonpharmacological treatment options, with reference to other sources of information on the topic. •First-line therapies https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-academy-sleep-medicine-2025a10004x9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •New treatment options https://reference.medscape.com/cc2/p10/guideline-essentials-2025-american-academy-sleep-medicine-2025a10004x9?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108

ACUTE MIGRAINE (IHS)

ACUTE MIGRAINE (IHS) •Initiating higher triptan doses Acute Pharmacological Treatment of Migraine Source: International Headache Society https://reference.medscape.com/cc2/p10/international-headache-society-global-practice-2024a1000ieu?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 This Medscape summary of International Headache Society guidance covers practical, international, evidence-based recommendations from the International Headache Society on the acute pharmacological management of migraine. Recommendations are categorised into two levels: optimal and essential. The optimal level is intended for settings where most drug treatments are available. The essential level is intended for underserved areas, where treatment options are limited or that can only count on the medications listed in the World Health Organization (WHO) model list of essential medicines (EML). •Combining triptans and NSAIDs https://reference.medscape.com/cc2/p10/international-headache-society-global-practice-2024a1000ieu?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108 •Treatment of early vomiting https://reference.medscape.com/cc2/p10/international-headache-society-global-practice-2024a1000ieu?ecd=WNL_drugguide_251216_MSCPREF_neuro_etid7957108&uac=148436CN&impID=7957108